Spark Investment Management’s Karyopharm Therapeutics KPTI Stock Holding History

Spark Investment Management’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-720	Closed	-$207K	–	459
2019 Q4	$207K	Buy	+720	New	+$156K	0.02%	456
2019 Q3	–	Sell	-5,797	Closed	-$520K	–	458
2019 Q2	$520K	Sell	5,797 -12,056	-68%	-$968K	0.04%	367
2019 Q1	$1.56M	Buy	17,853 +6,262	+54%	+$694K	0.07%	284
2018 Q4	$1.63M	Buy	11,591 +7,451	+180%	+$1.26M	0.11%	233
2018 Q3	$1.06M	Buy	+4,140	New	+$1.14M	0.06%	371
2014 Q3	–	Sell	-2,120	Closed	-$1.48M	–	695
2014 Q2	$1.48M	Buy	2,120 +987	+87%	+$459K	0.22%	152
2014 Q1	$524K	Sell	1,133 -480	-30%	-$243K	0.08%	346
2013 Q4	$553K	Buy	+1,613	New	+$446K	0.1%	319

Other funds holding KPTI

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Spark Investment Management's KPTI Position: Q1 2020 in Review

Spark Investment Management sold out of Karyopharm Therapeutics (KPTI) in Q1 2020, closing a stake of 720 shares — an estimated $207K sold.

Spark Investment Management first reported a position in KPTI in Q4 2013 and held it in 8 quarters. The position peaked at $1.63M in Q4 2018. 136 funds tracked by Wall St. Rank hold KPTI as of Q1 2020.

Spark Investment Management reported no remaining Karyopharm Therapeutics position as of Q1 2020 after selling out during the quarter.
Spark Investment Management sold 720 Karyopharm Therapeutics shares in Q1 2020, an estimated $207K.
Spark Investment Management first reported a position in Karyopharm Therapeutics in Q4 2013 and held it in 8 quarters.
Spark Investment Management's Karyopharm Therapeutics position peaked at $1.63M in Q4 2018.
136 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2020.

Based on Spark Investment Management's 13F filing for Q1 2020, filed 12 May 2020.